-
Study: Lyft partnership reduces costs, waiting times for chronically ill seniors
In a study published Tuesday in JAMA, Anthem subsidiary CareMore Health Plan demonstrated how it collaborated with the ride service Lyft to reduce patient waiting times by 30 percent and cut per-ride costs by 32.4 percent.
-
Hopkins, Salk seek new treatments for schizophrenia, bipolar disorder
The consortium will use induced pluripotent stem cell (iPSC) technology — a type of stem cell that can be generated from adult stem cells — to find better treatments for the two psychiatric conditions.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Home care IT vendor ClearCare gets $60M from Battery Ventures
ClearCare has raised $76 million to date from Battery Ventures, McKesson, Bessemer Venture Partners, Voyager Capital, Cambia Health Solutions and Qualcomm Ventures.
-
Thar Pharma seeks $50M IPO to develop drug for chronic pain
Thar produces an oral version of an existing intravenous drug used to treat the estimated 80,000 Americans diagnosed annually with complex regional pain syndrome.
-
Regenstrief hopes to create comprehensive patient profile by leveraging interoperability standard
“This brings us much closer to a ‘lingua franca’ for health information, so clinicians finally have complete information available about their patients.”
-
Hospitals, Devices & Diagnostics
New MRI technology could be placed outside shielded zones
Aspect Imaging and design firm frog are working together to develop a new MRI technology that’s cheaper and can be placed outside shielded areas in a hospital.
-
Devices & Diagnostics, Startups
J&J’s venture arm backs CVRx in $93 million funding round
CVRx, which has struggled to get the FDA nod for an earlier generation device, will use the money to progress its pivotal clinical trial in the U.S. to treat patients with congestive heart failure using neuromodulation.
-
International coalition putting $350M behind CARB-X to fight drug-resistant bacteria
The collaborative brings together more acronyms than an army battle map, international drug research expertise and as much as $350 million in funding to tackle this looming crisis.
-
Startup device maker takes aim at hospital pressure ulcers
Bruin Biometrics is connecting its wireless pressure ulcer detector, the SEM Scanner, to a digital registry for pressure ulcers known as PUNT (Pressure Ulcer Notification Tool).
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Sanford Health steps up precision medicine with pharmacogenomics program
Sanford Health, a 43-hospital health system based in Sioux Falls, South Dakota, has contracted with Bellevue, Washington-based Translational Software to provide pharmacogenomics services to its hospitals and nearly 250 clinics in nine states.
-
Imaging technology allows 3-D visualization of Alzheimer’s-related plaques
The Fisher Center for Alzheimer’s Research Foundation is funding a new technology that allows greater visualization of amyloid plaques as well as other Alzheimer’s markers, such as tau proteins and vasculature and microglia activation.
-
Bill would lift Medicare Advantage restrictions on end-stage renal disease
The bill, known as the ESRD Choice Act (H.R. 5?659), would allow enrollment in the Medicare managed care plans to ESRD patients undergoing dialysis treatment.
-
Immuno-microbiome companies Evelo Biosciences and Epiva Biosciences merge
“It was driven by the recognition that fundamentally the biological platform for both companies was a mirror image. We both independently uncovered the biology of the immune-microbiome.”
-
With devaluation, Zenefits tries to bounce back from scandal
In the revaluation, the onetime Silicon Valley darling allowed large investors to increase their ownership stake in the company in the wake of a scandal.